## W0200153312 Comparison

```
AAM39781 standard; Protein; 772 AA
ID
XX
     AAM39781;
AC
XX
     22-OCT-2001 (first entry)
DT
XX
DE
     Human polypeptide SEQ ID NO 2926.
XX
     Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW
KW
     peripheral nervous system; neuropathy; central nervous system; CNS;
     Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW
KW
     amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW
     chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
     leukaemia.
KW
XX
OS
     Homo sapiens.
XX
     WO200153312-A1.
PN
XX
PD
     26-JUL-2001.
XX
     26-DEC-2000; 2000WO-US34263.
PF
XX
     21-JAN-2000; 2000US-0488725.
PR
     25-APR-2000; 2000US-0552317.
PR
     09-JUL-2000; 2000US-0598042.
PR
     19-JUL-2000; 2000US-0620312.
PR
     03-AUG-2000; 2000US-0653450.
PR
     14-SEP-2000; 2000US-0662191.
PR
     19-OCT-2000; 2000US-0693036.
PR
     29-NOV-2000; 2000US-0727344.
PR
XX
PΑ
     (HYSE-) HYSEQ INC.
XX
ΡI
     Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PΙ
     Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y,
PΙ
     Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR
     WPI; 2001-442253/47.
DR
     N-PSDB; AAI58937.
XX
     Novel nucleic acids and polypeptides, useful for treating disorders
PT
PT
     such as central nervous system injuries -
XX
PS
     Example 4; SEQ ID NO 2926; 10078pp; English.
XX
CC
     The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC
     the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC
     immunosuppressant and cytostatic activity. The polynucleotides are useful
CC
     in gene therapy. A composition containing a polypeptide or polynucleotide
     of the invention may be used to treat diseases of the peripheral nervous
CC
CC
     system, such as peripheral nervous injuries, peripheral neuropathy and
CC
     localised neuropathies and central nervous system diseases, such as
CC
     Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC
     lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC
     utilisation of the activities such as: Immune system suppression,
     Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
```

```
and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC
CC
    assays for receptor activity, arthritis and inflammation, leukaemias and
CC
    C.N.S disorders.
    Note: The sequence data for this patent did not form part of the printed
CC
    specification.
CC
XX
               772 AA;
SQ
    Sequence
 Query Match
                         100.0%; Score 4037; DB 22; Length 772;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 772; Conservative 0; Mismatches
                                                 0; Indels
                                                             0; Gaps
                                                                          0;
```

	Matches	772;	Conserva	ative	0;	Misma	tches	0;	Indels	0;	Gaps	0;
Qу		111111	LALLRPALE	111111	11111	111111	$11\overline{11111}$	11111	1111111	ЙШШ	ļ	
Db	1	mrissi	lallrpalp	olilgis.	Igcs1:	slirvs	widdede	dpcve	avgerggp	pqnpdsra	c 60	
Qу	61		DFKPRIVPY									
Db	61	ldqsde	dfkprivpy	yrdpnk	oykkv.	lrtryi	qtelgsr	erllv	avltsrat	tlstlava	120	
ΩУ	121		HFPRLLYFT	_		~						
Db	121		hfprllyft									
Qу	181		vqaprlaai 									
Db	181	mqddty	vqaprlaal	aghlsir.	nqdly	lgraee	figageq	arych	ggfgylls	srslllrl	240	
Qу	241		RGDILSARP									
Db	241		rgdilsarp									
Qу	301		PVSEGTLMY									
Db	301		pvsegtlmy									
Qу	361		HSRFEVLGW									
Db	361		hsrfevlgw									
Qу	421		QRLLNGYRR									
Db	421		qrllngyrr									
Qу	481		TRVQLVLPL									
Db	481		trvqlvlpl									
Qу	541		AAAAELERR									
Db	541		aaaelerr									
Qу	601		CRMNAISGW									
Db	601		crmnaisgw									

```
661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGLHLFRAV 720
Qу
         661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsglhlfrav 720
Db
      721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQEQANST 772
Qу
         721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqeqanst 772
Db
RESULT
AAB80269
    AAB80269 standard; Protein; 772 AA.
XX
     AAB80269;
AC
XX
DT
    24-APR-2001 (first entry)
XX
    Human PRO339 protein.
DE
XX
    Humany PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW
KW
    antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
    antian diogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW
    antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW
    ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
ΚW
KW
    ischaemia; inflammation.
XX
os
    Homo sapiens.
XX
ΡN
    WO200104311-A1.
XX
PD
    18-JAN-2001.
XX
    22-FEB-2000; 20Q0WO-US04414.
PF
XX
    07-JUL-1999;
                  99\us-0143048.
PR
PR
    26-JUL-1999;
                  99ປ່ຽ-0145698.
                   99US\0146222.
PR
    28-JUL-1999;
                   99WO-US20594.
PR
    08-SEP-1999;
                   99WO-U$20944.
PR
    13-SEP-1999;
PR
    15-SEP-1999;
                   99WO-US21090.
                   99WO-US2\1547.
PR
    15-SEP-1999;
PR
    05-OCT-1999;
                   99WO-US23Q89.
PR
    29-NOV-1999;
                   99WO-US28214.
    30-NOV-1999;
                   99WO-US28313
PR
    16-DEC-1999;
                   99WO-US30095.
PR
PR
    20-DEC-1999;
                   99WO-US30911.
PR
    20-DEC-1999;
                   99WO-US30999.
PR
    05-JAN-2000;
                   99WO-US00219.
XX
    (GETH ) GENENTECH INC.
PA
XX
PΙ
    Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
ΡI
    Filvaroff E, Fong S, Gao W, Gerber H,
                                            Gerritsen ME, Goddard A;
    Godowski PJ, Grimaldi CJ, Gurney AL,
PI
                                         \Hillan KJ, Kljavin IJ;
PI
    Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PΙ
    Williams PM, Wood WI;
XX
```

```
ID
     AAI58937 standard; cDNA; 2710 BP.
     AAI58937;
AC
DΤ
     22-OCT-2001 (first entry)
     Human polynucleotide SEQ ID NO 1140.
DE
     Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW
     peripheral nervous system; neuropathy; central nervous system; CNS;
KW
     Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
     amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW
     chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW
ĸw
     leukaemia; ss.
os
     Homo sapiens.
XX
     WO200153312-A1.
PΝ
XX
PD
     26-JUL-2001.
XX
PF
     26-DEC-2000; 2000WO-US34263.
XX
     21-JAN-2000; 2000US-0488725.
PR
     25-APR-2000; 2000US-0552317.
PR
     09-JUL-2000; 2000US-0598042.
PR
PR
     19-JUL-2000; 2000US-0620312.
     03-AUG-2000; 2000US-0653450.
PR
     14-SEP-2000; 2000US-0662191.
PR
     19-OCT-2000; 2000US-0693036.
PR
     29-NOV-2000; 2000US-0727344.
PR
\mathbf{X}\mathbf{X}
PA
     (HYSE-) HYSEQ INC.
\mathbf{x}\mathbf{x}
     Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D; Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PΙ
ΡI
     Zhao QA, Zhou P, Goodrich R, Drmanac RT;
PΙ
XX
DR
     WPI; 2001-442253/47.
DR
     P-PSDB; AAM39781.
XX
     Novel nucleic acids and polypeptides, useful for treating disorders
PT
PT
     such as central nervous system injuries -
XX
PS
     Claim 1; SEQ ID NO 1140; 10078pp; English.
XX
CC
     The invention relates to human nucleic acids (AAI57798-AAI61369) and
     the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC
     immunosuppressant and cytostatic activity. The polynucleotides are useful
CC
     in gene therapy. A composition containing a polypeptide or polynucleotide
CC
     of the invention may be used to treat diseases of the peripheral nervous
CC
     system, such as peripheral nervous injuries, peripheral neuropathy and
CC
     localised neuropathies and central nervous system diseases, such as
CC
     Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC
     lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC
CC
     utilisation of the activities such as: Immune system suppression,
     Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC
     and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC
CC
     assays for receptor activity, arthritis and inflammation, leukaemias and
     C.N.S disorders.
CC
CC
     Note: The sequence data for this patent did not form part of the printed
     specification.
CC
ХX
     Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;
SO
 Query Match
                           96.5%; Score 2692; DB 22; Length 2710;
 Best Local Similarity
                          100.0%; Pred. No. 0;
 Matches 2692; Conservative
                                  0; Mismatches
                                                     0; Indels
                                                                   0; Gaps
                                                                                0;
```

Qγ

		111111111111111111111111111111111111111	
DЬ	7	ggggttagttccgacaccttcacagttgaagacaggcagaaggagttgtgaagacagg	66
Qy	158	acaatettettggggatgetggteetggaageeagegggeettgetetgtetttggeete	217
DЪ	67	acaatcttcttggggatgctggtcctggaagccagcgggccttgctcttttggcctc	126
Qy	218	attgaccccaggttctctggttaaaactgaaagcctactactggcctggtgcccatcaat	277
Db	127		186
Qy	278	ccattgatccttgaggctgtgccctggggcaccacctggcagggcctaccaccatgg	337
DЪ	187		246
Qу	338	actgagetecetgttggetetgetgeggeeagegetteceetcatettagggetgtetet	397
Db	247	actgagetccctgttggctctgctgcggccagcgcttcccctcatcttagggctgtctct	306
Qу	398	ggggtgcagcctgagcctcctgcgggtttcctggatccagggggaggagagaaagatccctg	457
DЪ	307		366
Qу	458	tgtcgaggctgtaggggagcgagggggcacagaatccagattcgagagctcggctaga	517
Db	367	tgtcgaggctgtaggggagcgaggagggcacacagaatccagattcgagatcggctaga	426
Qy	518	ccaaagtgatgaagacttcaaaccccggattgtcccctactacagggaccccaacaagcc	577
Db	427	ccaaagtgatgaagacttcaaaccccggattgtcccctactacagggaccccaacaagcc	486
Qy	578	ctacaagaaggtgctcaggactcggtacatccagacagagctgggctcccgtgagcggtt	637
Db	487	ctacaagaaggtgctcaggactcggtacatccagacagagctgggctcccgtgagcggtt	546
Qу	638	gctggtggctgtcctgacctcccgagctacactgtccacttttggccgtggctgtgaaccg	697
Db	547	getggtggetgteetgaeeteeegagetaeaetgteeaetttggeegtggetgtgaaeeg	606
Qy	698	tacggtggcccatcacttccctcggttactctacttcactgggcagcgggggcccgggc	757
Db	607	tacggtggcccatcacttccctcggttactctacttcactgggcagcggggggcccgggc	666
Qy	758	tecagcagggatgcaggtggtgtetcatggggatgagcggcccgcctggctcatgtcaga	817
DЪ	667	tecageaggatgeaggtggteteatggggatgageggeeegeetggeteatgteaga	726
Qу	818	gaccetgcgccacettcacacacactttggggccgactacgactggttettcatcatgca	877
Db	727	gaccetgcgccacettcacacacactttggggccgactacgactggttettcatcatgca	786
Qу		ggatgacacatatgtgcaggcccccgcctggcagcccttgctggccacctcagcatcaa	
Db	787	ggatgacacatatgtgcaggcccccgcctggcagcccttgctggccacctcagcatcaa	846
Qу	938	ccaagacctgtacttaggccgggcagaggagttcattggcgcaggcgagcccggta	997
Db		ccaagacctgtacttaggccgggcagaggagttcattggcgcaggcgagcaggcccggta	
Qy		ctgtcatgggggctttggctacctgttgtcacggagtctcctgcttcgtctgcggccaca	
Db	907	ctgtcatgggggctttggctacctgttgtcacggagtctcctgcttcgtctgcggccaca	966
Qy	1058	tetggatggetgeegaggagacatteteagtgeeegteetgaegagtggettggaegetg	
DΡ	967	totagetagetageageageaetatagatageatactaecagatagettageagea	1026

	Qy	1118	cctcattgactctctgggcgtcggctgtgtctcacagcaccaggggcagcagtatcgctc	1177
	Db	1027	cctcattgactctctgggcgtcggctgttctcacagcaccaggggcagcagtatcgctc	1086
	Qy	1178	atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc	1237
	DЪ	1087	atttgaactggccaaaaatagggaccctgagaaggaagggagctcggctttcctgagtgc	1146
	Qy	1238	cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaacgcttcag	1297
	Db	1147	cttcgccgtgcaccctgtctccgaaggtaccctcatgtaccggctccacaaaacgcttcag	1206
	Qу	1298	cgctctggagttggagcgggcttacagtgaaatagaacaactgcaggctcagatccggaa	1357
	Db	1207	egetetggagttggagegggettacagtgaaatagaacaaetgcaggetcagatccggaa	1266
	Qу	1358	cctgaccgtgctgacccccgaaggggaggcagggctgagctgaccgttgggctccctgc	1417
	Db	1267	cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgttgggctccctgc	1326
	Qy	1418	tcctttcacaccacactctcgctttgaggtgctggggctgggactacttcacagagcagca	1477
	Db	1327	teettteacaccacactetegetttgaggtgetgggetgg	1386
	Qy	1478	caccttctcctgtgcagatggggctcccaagtgcccactacagggggctagcagggcgga	1537
	Db	1387	cacctteteetgtgeagatggggeteeeaagtgeeeactacagggggetageagggegga	1446
	Qу	1538	cgtgggtgatgcgttggagactgcctggagcagctcaatcggcgctatcagccccgcct	1597
,	Db	1447	ogtgggtgatgcgttggagactgccctggagcagctcaatcggcgctatcagccccgcct	1506
	Qу	1598	gcgottccagaagcagcgactgctcaacggctatcggcgcttcgacccagcacggggcat	1657
	Db	1507	gegettecagaageagegaetgeteaaeggetateggegettegaeeeageaeggggeat	1566
	Qy	1658	ggagtacaccctggacctgctgttggaatgtgtgacacagcgtgggcaccgggggccct	1717
	Db	1567	ggagtacaccetggacctgctgttggaatgtgtgacacagcgtgggcaccggcgggccet	1626
	Qy		ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctaccta	
	Db		ggetegeagggteageetgetgeggeeaetgageegggtggaaateetaeeta	
	Qy		tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgctgc	
	Db		tgtcactgaggccacccgagtgcagctggtgctgccactcctggtggctgaagctgctgc	
	Qу		agccecggetttectegaggegtttgcagccaatgtcetggagccacgagaacatgcatt 	
	DЬ		agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt	
	Qy		getcaccetgttgctggtctacgggccacgagaaggtggccgtggagctccagacccatt	
	Db		geteaccetgttgetggtetacgggccacgagaaggtggccgtggagetccagacccatt	
	Qy Db		tcttggggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 	
	DD Qy		ctggctgctgtgcagcagcagcggagttagagcgaccgtaccctgggacgaggctggc	
	Dρ			
	DБ Qy		gaagcaccctgtggacactctcttcttccttaccaccgtgtggacaaaggcctgggcccga	
	×1	24,0		,

Db	1987		2046
Qу	2138	${\tt agtectcaaccgctgtcgcatgaatgccatctctggctggcaggccttctttccagtcca}$	2197
Db	2047	agtcctcaaccgctgtcgcatgaatgccatctctggctgg	2106
Qу	2198	tttccaggagttcaatcctgccctgtcaccacagagatcaccccagggccccgggggc	2257
Db	2107		2166
Qy	2258	tggccctgacccccctccctctggtgctgacccctcccggggggctcctataggggg	2317
Db	2167		2226
Qy	2318	gagatttgaccggcaggcttctgcggagggctgcttctacaacgctgactacctggcggc	2377
Db	2227		2286
Qу	2378	ccgagcccggctggcaggtgaactggcaggcaggaagaggaagccctggaggggct	2437
Db	2287		2346
Qy	2438	ggaggtgatggatgttttcctccggttctcagggctccacctctttcgggccgtagagcc	2497
Db	2347	ggaggtgatggatgttttcctccggttctcagggctccacctctttcgggccgtagagcc	2406
Qy	2498	agggctggtgcagaagttctccctgcgagactgcagcccacggctcagtgaagaactcta	2557
Db	2407	agggctggtgcagaagttctccctgcgagactgcagcccacggctcagtgaagaactcta	2466
Qy	2558	ccaccgctgccgcctcagcaacctggagggctaggggccgtgcccagctggctatggc	2617
Db	2467	ccaccgctgccgcctcagcaacctggaggggctagggggccgtgcccagctggctatggc	2526
Qy	2618	tetetttgageaggageaggeeaatageacttageeegeetgggggeeetaaceteatta	2677
Db	2527	tetetttgageaggageaggeeaatageaettageeegeetgggggeeetaaceteatta	2586
Qу	2678	cctttcctttgtctgcctcagccccaggaagggcaaggcaagatggtggacagatagaga	2737
Db	2587	cctttcctttgtctgcctcagccccaggaagggcaaggcaagatggtggacagatagaga	2646
Qy	2738	attgttgctgtattttttaaatatgaaaatgttattaaacatgtcttctgcc 2789	
Db	2647	attqttqctqtattttttaaatatqaaaatqttattaaacatqtcttctqcc 2698	